Effect of PKC-β signaling pathway on expression of MCP-1 and VCAM-1 in different cell models in response to advanced glycation end products (AGEs)

Toxins

Volumn 7, Issue 5, 2015, Pages 1722-1737

  Rempel, Lisienny C T ^a   Finco, Alessandra B ^a   Maciel, Rayana A P ^a   Bosquetti, Bruna ^a   Alvarenga, Larissa M ^a   Souza, Wesley M ^a,b   Pecoits Filho, Roberto ^c   Stinghen, Andréa E M ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSIDADE TUIUTI DO PARANÁ   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

AGEs; Chronic kidney disease; Endothelial dysfunction; MCP 1; PKC pathway; VCAM 1

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ENDOTOXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE C BETA; VASCULAR CELL ADHESION MOLECULE 1; CCL2 PROTEIN, HUMAN;

ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CELL VIABILITY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIMULUS LYSATE TEST; MONOCYTE; MTT ASSAY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL SURVIVAL; COCULTURE; DRUG EFFECTS; METABOLISM; U-937 CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; CELL SURVIVAL; CHEMOKINE CCL2; COCULTURE TECHNIQUES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; PROTEIN KINASE C BETA; SIGNAL TRANSDUCTION; U937 CELLS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84929377539     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins7051722     Document Type: Article

References (44)

1. Meijers, B.K.; de Preter, V.; Verbeke, K.; Vanrenterghem, Y.; Evenepoel, P. P-cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol. Dial. Transplant. 2009, 25, 219–224.
2. Nahas, M. Cardio-Kidney-Damage: A unifying concept. Kidney Int. 2010, 78, 14–18.
3. Stinghen, A.E.M.; Pecoits-Filho, R. Vascular damage in kidney disease: Beyond hypertension. Int. J. Hypertens. 2011, 2011, 232683, doi:10.4061/2011/232683.
4. Stinghen, A.E.M.; Goncalves, S.M.; Martines, E.G.; Nakao, L.S.; Riella, M.C.; Aita, C.A.; Pecoits-Filho, R. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin. Pract. 2009, 111, c117–c126.
5. Schwedler, S.; Schinzel, R.; Vaith, P.; Wanner, C. Inflammation and advanced glycation end products in uremia: Simple coexistence, potentiation or causal relationship? Kidney Int. 2001, 59, S32–S36.
6. Semba, R.D.; Nicklett, E.J.; Ferruci, L. Does accumulation of advanced glycation end products contribute to the aging phenotype? J. Gerontol. A Biol. Sci. Med. Sci. 2010, 65, 963–975.
7. Piperi, C.; Adamopoulos, C.; Dalagiorgou, G.; Diamanti-Kandarakis, E.; Papavassiliou, A.G. Crosstalk between advanced glycation and endoplasmic reticulum stress: Emerging therapeutic targeting for metabolic diseases. J. Clin. Endocrinol. Metab. 2012, 97, 2231–2242.
8. Thornalley, P.J.; Rabbani, N. Highlights and hotspots of protein glycation in end-stage renal disease. Semin. Dial. 2009, 22, 400–404.
9. Alhamdani, M.S.; Al-Azzawie, H.F.; Abbas, F.K. Decreased formation of advanced glycation end-products in peritoneal fluid by carnosine and related peptides. Perit. Dial. Int. 2007, 27, 86–89.
10. Yubero-Serrano, E.M.; Woodward, M.; Poretsky, L.; Vlassara, H.; Striker, G.E. Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 2015, 10, 759–766.
11. Meerwaldt, R.; Zeebregts, C.J.; Navis, G.; Hillebrands, J.L.; Lefrandt, J.D.; Smit, A.J. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am. J. Kidney Dis. 2009, 53, 138–150.
12. Zieman, S.; Kass, D. Advanced glycation end product cross-linking: Pathophysiologic role and therapeutic target in cardiovascular disease. Congest. Heart Fail. 2004, 10, 144–149.
13. Linden, E.; Cai, W.; He, J.C.; Xue, C.; Liz, Z.; Winston, J.; Vlassara, H.; Uribarri, J. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin. J. Am. Soc. Nephrol. 2008, 3, 691–698.
14. Brownlee, M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005, 54, 1615–1625.
15. Tanji, N.; Markowitz, G.S.; Fu, C.; Kislinger, T.; Taguchi, A.; Pischetsrieder, M.; Stern, D.; Schmidt, A.M.; D’Agati, V.D. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 2000, 11, 1656–1666.
16. Liu, J.; Huang, K.; Cai, G.Y.; Chen, X.M.; Yang, J.R.; Lin, L.R.; Yang, J.; Huo, B.G.; Zhan, J.; He, Y.N. Receptor for advanced glycation end-products promotes premature senescence of proximal tubular epithelial cells via activation of endoplasmic reticulum stress dependent p21 signaling. Cell. Signal. 2014, 26, 110–121.
17. Tumur, Z.; Shimizu, H.; Enomoto, A.; Miyazaki, H.; Niwa, T. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. Am. J. Nephrol. 2010, 31, 435–441.
18. Pongor, S.; Ulrich, P.C.; Bencsath, F.A.; Cerami, A. Aging of proteins: Isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc. Natl. Acad. Sci. USA 1984, 81, 2684–2688.
19. Recio-Mayoral, A.; Banerjee, D.; Streather, C.; Kaski, J.C. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis 2011, 216, 446–451.
20. Jaipersad, A.S.; Lip, G.Y.; Silverman, S.; Shantsila, E. The role of monocytes in angiogenesis and atherosclerosis. J. Am. Coll. Cardiol. 2014, 63, 1–11.
21. Aiello, R.J.; Bourassa, P.A.; Lindsey, S.; Weng, W.; Natoli, E.; Rollins, B.J.; Milos, P.M. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 1518–1525.
22. Xu, B.; Chibber, R.; Ruggiero, D.; Kohner, E.; Ritter, J.; Ferro, A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J. 2003, 17, 1289–1291.
23. Kaneko, M.; Bucciarelli, L.; Hwang, Y.C.; Lee, L.; Yan, S.F.; Schmidt, A.M.; Ramasamy, R. Aldose reductase and AGE-RAGE pathways: Key players in myocardial ischemic injury. Ann. N.Y. Acad. Sci. 2005, 1043, 702–709.
24. Liu, Y.; Ma, Y.; Wang, R. Advanced glycation end products accelerate ischemia/reperfusion injury through receptor of advanced end product/nitrative thioredoxin inactivation in cardiac microvascular endothelial cells. Antioxid. Redox Signal. 2011, 15, 1769–1778.
25. Dal-Pizzol, F.; Pasquali, M.; Quevedo, J.; Gelain, D.P.; Moreira, J.C. Is there a role for high mobility group box 1 and the receptor for advanced glycation end products in the genesis of long-term cognitive impairment in sepsis survivors? Mol. Med. 2012, 18, 1357–1358.
26. Xu, Y.; Wang, S.; Feng, L.; Zhu, Q.; Xiang, P.; He, B. Blockade of PKC-beta protects HUVEC from advanced glycation end products induced inflammation. Int. Immunopharmacol. 2010, 10, 1552–1559.
27. Fukami, K.; Yamagishi, S.; Okuda, S. Role of AGEs-RAGE system in cardiovascular disease. Curr. Pharm. Des. 2014, 20, 2395–2402.
28. Basta, G.; Lazzerini, G.; Del Turco, S.; Ratto, G.M.; Schimidt, A.M.; de Catarina, R. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1401–1407.
29. Bu, D.X.; Rai, V.; Shen, X.; Rosario, R.; Lu, Y.; D’Agati, V.; Yan, S.F.; Friedman, R.A.; Nuglozeh, E.; Schimidt, A.M. Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ. Res. 2010, 106, 1040–1051.
30. Wang, J.; Liu, H.; Chen, B.; Li, Q.; Huang, X.; Wang, L.; Guo, X.; Huang, Q. RhoA/ROCK-dependent moesin phosphorylation regulates AGE-induced endothelial cellular response. Cardiovasc. Diabetol. 2012, 11, 7, doi:10.1186/1475-2840-11-7.
31. Matasui, T.; Nishino, Y.; Maeda, S.; Takeuchi, M.; Yamagishi, S. Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells. Microvasc. Res. 2011, 81, 269–273.
32. Ramli, J.; Calderon Artero, P.; Block, R.C.; Mousa, S.A. Novel therapeutic targets for preserving a healthy endothelium: Strategies for reducing the risk of vascular and cardiovascular disease. Cardiol. J. 2011, 18, 352–363.
33. Bordoni, V.; de Cal, M.; Rassu, M.; Cavvavillan, S.; Segala, C.; Bonello, M.; Ranishta, R.; Andrikos, E.; Yavuz, A.; Salvatori, G. et al. Protective effect of urate oxidase on uric acid induced-monocyte apoptosis. Curr. Drug Discov. Technol. 2005, 2, 29–36.
34. Diaz-Buxo, J.A.; Woods, H.F. Protecting the endothelium: A new focus for management of chronic kidney disease. Hemodial. Int. 2006, 10, 42–48.
35. Ward, M.S.; Fortheringham, A.K.; Cooper, M.E.; Forbes, J.M. Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease. Curr. Opin. Pharmacol. 2013, 13, 654–661.
36. Schmidt, A.M.; Hori, O.; Chen, J.X.; Li, J.F.; Crandall, J.; Zhang, J.; Cao, R.; Yan, S.D.; Brett, J.; Stern, D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Investig. 1995, 96, 1395–1403.
37. Bucciarelli, L.G.; Wendt, T.; Rong, L.; Lalla, E.; Hofmann, M.A.; Goova, M.T.; Taquchi, A.; Yan, S.F.; Stern, D.M.; Schmidt, A.M. RAGE is a multiligand receptor of the immunoglobulin superfamily: Implications for homeostasis and chronic disease. Cell. Mol. Life Sci. 2002, 59, 1117–1128.
38. Naum, M.H.; Lee, H.S.; Seomun, Y.; Lee, Y.; Lee, K.W. Monocyte-endothelium-smooth muscle cell interaction in co-culture: Proliferation and cytokine productions in response to advanced glycation end products. Biochim. Biophys. Acta 2011, 1810, 907–912.
39. Lukacs, N.W.; Strieter, R.M.; Elner, V.; Evanoff, H.L.; Burdick, M.D.; Kunkel, S.L. Production of chemokines, interleukin-8 and monocyte chemoattractant protein-1, during monocyte: Endothelial cell interactions. Blood 1995, 86, 2767–2773.
40. Iwashima, Y.; Eto, M.; Horiuchi, S.; Sano, H. Advanced glycation end product-induced peroxisome proliferator-activated receptor gamma gene expression in the cultured mesangial cells. Biochem. Biophys. Res. Commun. 1999, 264, 441–448.
41. Lowry, O.H.; Rosebrough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265–275.
42. Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227, 680–685.
43. Jaffe, E.A.; Nachman, R.L.; Becker, C.G.; Minick, C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Investig. 1973, 52, 2745–2756.
44. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55–63.